Key result
Obesity and type 2 diabetes were associated with significantly decreased circulating betatrophin levels compared to lean normoglycemic individuals (13.5 vs 45.1 ng/mL; P<0.001).
Population
153 subjects including 75 obese normoglycemic, 30 obese with impaired glucose tolerance, 15 obese with type…
Design
Cross-sectional
Authors
Loading...
No immediate clinical implications for betatrophin measurement; leaves open its utility as a cardiometabolic biomarker pending prospective validation.
Cross-Sectional (n=153)
p-value: p=<.001
Serum betatrophin is decreased in human obesity and further reduced in obesity-associated insulin resistance, suggesting it may serve as a potential biomarker for cardiometabolic risk.
Gómez‐Ambrosi et al. (2014) conducted a cross-sectional in Obesity and Type 2 Diabetes (n=153). Obesity and Type 2 Diabetes vs. Lean normoglycemic individuals was evaluated on Circulating concentrations of betatrophin (p=<.001). Obesity and type 2 diabetes were associated with significantly decreased circulating betatrophin levels compared to lean normoglycemic individuals (13.5 vs 45.1 ng/mL; P<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: